Frequently Asked Questions
Factors such as increase in geriatric population and increase in oral drugs are acting as the major drivers for the global intestinal ischemia market.
Johnson & Johnson Services, Inc (U.S.), Sanofi (France), Bayer AG (Germany), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Melinta Therapeutics, INC (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), Pfizer Inc (U.S.), Novartis AG (Switzerland), Mylan N.V (U.S.), Lupin (India), Amneal Pharmaceuticals Inc (U.S.), Zydus Cadila (India), Bausch Health (Canada), Teva Pharmaceutical Industries Ltd (Israel).
The major countries covered in the Intestinal Ischemia Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
